World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   846 records for 189 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusMain ID Public TitleDate of Registration
RecruitingNCT02404389
Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
23/01/2015
AuthorisedEUCTR2014-003613-28-AT
study in patients with actinic keratosis (an disease of the skin) with the aim to evaluate the efficacy, the safety and the pharmacokinetics (way the body absorbs, distributes, and gets ride of the drug) of LFX453 after multiple applications to the skin 05/11/2014
RecruitingNCT02304484
Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab 07/10/2014
RecruitingNCT02251496
COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks.
25/09/2014
Not recruitingNCT02236455
Effects of Complementary Therapies Delivered Via Mobile Technologies
04/09/2014
AuthorisedEUCTR2013-001811-56-AT
The effect of oral antibiotics on clinical and patient-centered outcomes of implant therapy and simultaneous guided bone regeneration. A randomised controlled clinical trial.
01/09/2014
RecruitingNCT02226120
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-001971-30-LVSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction06/10/2014
AuthorisedEUCTR2014-001971-30-LTSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction22/10/2014
AuthorisedEUCTR2014-001971-30-PTSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction18/11/2014
AuthorisedEUCTR2014-001971-30-DKSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction20/11/2014
AuthorisedEUCTR2014-001971-30-HUSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction18/11/2014
AuthorisedEUCTR2014-001971-30-BESafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction19/01/2015
AuthorisedEUCTR2014-001971-30-FISafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction29/10/2014
AuthorisedEUCTR2014-001971-30-ITSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction16/12/2014
AuthorisedEUCTR2014-001971-30-EESafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction27/11/2014
AuthorisedEUCTR2014-001971-30-NLSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction04/11/2014
AuthorisedEUCTR2014-001971-30-DESafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction06/01/2015
AuthorisedEUCTR2014-001971-30-BGSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction06/02/2015
AuthorisedEUCTR2014-001971-30-SKSafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction12/11/2014
AuthorisedEUCTR2014-001971-30-SESafety and tolerability during open-label treatment with LCZ696 in patients with chronic heart failure and reduced ejection fraction10/11/2014
25/08/2014
RecruitingNCT02178956
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
Recruitment statusMain IDPublic titleDate of registration
Not RecruitingJPRN-JapicCTI-142690A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER)24/10/2014
AuthorisedEUCTR2014-000774-18-LTThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).04/09/2014
AuthorisedEUCTR2014-000774-18-ESThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).22/08/2014
AuthorisedEUCTR2014-000774-18-GBThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).17/09/2014
AuthorisedEUCTR2014-000774-18-DEThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).09/09/2014
AuthorisedEUCTR2014-000774-18-BEThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).22/01/2015
AuthorisedEUCTR2014-000774-18-ITThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).18/09/2014
AuthorisedEUCTR2014-000774-18-HUThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).09/09/2014
AuthorisedEUCTR2014-000774-18-PLThe purpose of this study is to find out whether it is better to receive treatment with paclitaxel, a standard chemotherapy, given in combination with a new drug, BBI608, or better to receive treatment with paclitaxel alone for stomach and gastroesophageal junction cancer. To do this, half of the patients in this study will receive paclitaxel and BBI608 and the other half will receive paclitaxel and a placebo (a substance that is designed not to do anything).15/09/2014
27/06/2014
RecruitingNCT02156804
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-001286-28-ATA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-BEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.23/07/2014
AuthorisedEUCTR2014-001286-28-ESA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-DEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.01/08/2014
AuthorisedEUCTR2014-001286-28-NLA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.06/08/2014
AuthorisedEUCTR2014-001286-28-PTA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.29/08/2014
AuthorisedEUCTR2014-001286-28-SEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.30/09/2014
AuthorisedEUCTR2014-001286-28-FIA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.17/10/2014
AuthorisedEUCTR2014-001286-28-DKA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.13/08/2014
AuthorisedEUCTR2014-001286-28-ITA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.31/07/2014
AuthorisedEUCTR2014-001286-28-IEA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.11/09/2014
AuthorisedEUCTR2014-001286-28-GBA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.04/08/2014
AuthorisedEUCTR2014-001286-28-HUA multicenter clinical study with Nivolumab for subjects with confirmed stage III or stage IV melanoma post treament with an Anti-CTLA-4 antibody.29/12/2014
RecruitingDRKS00006730A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody08/12/2014
29/05/2014
RecruitingNCT02166736
Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome
07/05/2014
    
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history